Labiotech.eu’s Post

There's been some really exciting news for Nimbus Therapeutics today as they closed a $210 million private investment round, led by GV (Google Ventures), SR One Capital Management and Atlas Venture. This investment round, while already being one of the biggest of 2023, follow up on a sale of Nimbus' experimental autoimmune medicine to Takeda for a massive $6 billion earlier this year and a previous investment round of $125m last September. To date, Nimbus have raised a huge $427m. Nimbus focuses on developing novel therapies for treatment of cancer, inflammatory and autoimmune conditions and metabolic diseases using small molecule. They utilise some unique technologies to develop these therapies, including machine learning-based predictive modeling approaches. Follow Warman O'Brien for all the latest news in the Life Sciences industry! #clinicalresearch #pharmaceutical #biotechnology #goodnews

We have compiled a comprehensive list of the most significant #biotechinvestments that went to private companies around the world in August, sourced directly from Crunchbase! 💰 The biggest #fundingrounds went to companies focused on #immunology, #geneticdisorders, and #metabolicdisorders, with the companies Genesis Therapeutics, ADARx Pharmaceuticals Inc., and Abcuro, Inc bagging the biggest investments. 🚀 But they are not alone. Many other visionary companies also secured impressive funding rounds like Rapport Therapeutics, Alltrna, Neurophth Therapeutics / 纽福斯生物科技有限公司, Epigenic Therapeutics, and Newlight Technologies, Inc., just to name a few. Dive deeper into the details by checking out our latest article by Willow Shah-Neville! 👇 https://lnkd.in/dw3nMUwz #biotech #biotechnews #biotechfinancing #biotechfunding

UNP Scores $32M for AI-Powered Macrocycle Therapeutics - HIT Consultant #UNP Scores $32M for AI-Powered Macrocycle Therapeutics #Summary: UNP, a healthcare technology company, has raised $32 million in funding for its AI-powered macrocycle therapeutics. The company aims to develop novel treatments for diseases that are currently difficult to treat. The funding will be used to advance the company's drug discovery platform and accelerate the development of its pipeline. UNP's technology combines artificial intelligence and machine learning to design and optimize macrocycles, which are large, complex molecules that can interact with disease targets. The company's approach has the potential to revolutionize drug discovery and lead to the development of more effective therapies. #Introduction: UNP, a healthcare technology company, has secured $32 million in funding ai.mediformatica.com #platform #funding #oncology #biotech #design #globalhealth #health #healthinnovation #innovation #medical #merckglobalhealthinnovationfund #seriesa #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3tp5PyH)

Private Biotech investment is on the steady rise reaching new highs in April with $3.1 billion raised that is surpassing previous three months activity according to Labiotech.eu report (https://lnkd.in/gUY2_xc7). In terms of geography, Europe and Asia-Pacific are trailing US. Among specific therapeutic areas Biotech companies developing Oncology assets are attracting largest investment that went solely to US and Asia-Pacific regions. This brings a question if European Biotech companies developing Oncology drugs face some unique challenges despite a very active recent trend of M&A. During 2023 there was high activity involving European based Biotechs with oncology pipeline. Interest in ADCs drove a licensing deal between Synaffix and MacroGenics, followed by the acquisition of Synaffix by Lonza. In addition, radiopharmaceutical Biotech ITM Isotope Technologies Munich raised one of the largest private investment rounds in European Biotech in 2023. In 2024 MorphoSys was acquired by Novartis, RedX Pharma was acquired by Jazz Pharmaceuticals, and Autolus Therapeutics was acquired by Bio NTech SE in February. Interesting to follow trends for Europe and see if there is influence of fragmented nature of the EU healthcare market making drug adoption prediction complex, possibly more risk-averse approach of EU-based buyers, as well as evolution of global reimbursement market on financial dynamics of the EU Biotech activity. #Biotech #Europe #US #Asia-pacific #M&A #private funding #therapeutic focus #oncology #ADC #radiopharmaceuticals

10 Noteworthy Global Biotech Companies that Got Funded in the first Quarter of 2024 According to data sourced from Crunchbase, the funding for Biotech companies represents a 161 percent upsurge compared to the USD 1.1 billion raised by the largest funding rounds which involved healthcare-focused biotech companies in the first quarter of 2023. Read the full article: https://goo.su/HCqWR By Samrat Pradhan, Managing Editor, #FinanceOutlookIndia Zephyr AI Yiyuan Yin FogPharma Mike Nolan Andrew Chi Baiteng Zhao Tubulis GmbH Laura Shawver Rakuten Medical Clasp Therapeutics Greg Chow, Freenome Diagonal Therapeutics Jixing Pharmaceuticals Obsidian Therapeutics Alamar Biosciences, Inc. ARS Pharmaceuticals, Inc. Nadia Agopyan, Ph.D., RAC Mark M, Sionna Therapeutics BlossomHill Therapeutics, Inc. BJ Sullivan, PhD, BioAge Labs Catherine Priest, Neurona Therapeutics #GlobalBiotech #FirstQuarter2024 #Biotechnologyindustry #FundingRounds #EmergingBiotechFirms #VentureCapital #TechnologicalAdvances #InnovationSpotlight

CTI Life Sciences Fund kicks off the new year with a new investment from its Fund III. CTI Life Sciences Fund participated in Amolyt Pharma's $138M USD Series C led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG). Amolyt Pharma is a clinical-stage biotechnology company developing life-changing treatments for patients suffering from rare endocrine and related diseases. Its lead asset, eneboparatide (AZP-3601), is a long-acting PTH1 receptor agonist and a potential best-in-class treatment for hypoparathyroidism. Its follow-on asset, AZP-3813, is a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.  Read more about this exciting news with the link below https://lnkd.in/gHPx4kDN

#fundingalert 💼Company: SynOx Therapeutics 💰Funding: $75Million ⚡Round: Series B  👥Investors: Forbion, HealthCap, Bioqube Ventures, Jon Edwards, PhD, and Carlo Incerti. Founded in November 2020, SynOx Therapeutics Ltd.'s only goal is to develop emactuzumab for use in treating diffuse tenosynovial giant cell tumours (TGCT) and other conditions. With a solid track record of developing biopharma enterprises, SynOx has the support of a syndicate of investors. Biotech startup. The money will be used by the business to provide registrational Phase 3 clinical and CMC data for emactuzumab, a monoclonal antibody (mAb) that inhibits CSF-1(R) and may be the best in class for treating Tenosynovial Giant Cell Tumours (TGCT). Raymond Barlow, Hamina Patel, MB BCh MSc MRCPI, Broes Naeye, Sarah Clare, Sander Veltkamp. Read more - https://lnkd.in/gs-h6Kyd To share your startup story write us on - contact@startuprise.co.uk #SynOxTherapeutics #biopharma #Biotechstartup #funding #fundingnews #news #startupnews #news #startuprise

Do you want to learn more about some of the top biotech companies based in Denmark? 🇩🇰 In recent years, Denmark’s life sciences sector has accelerated its output of high-quality research, as the country was ranked 16th overall for biological sciences-related output in 2022. 🚀 It is also among the fastest-growing nations in Europe for biotech investment, hitting $434 million in 2021. 💰 Check out our latest article as we take a look at 9 biotech companies in Denmark leading innovation in the sector. 👇️ https://lnkd.in/dfcA8RCn #biotechindenmark #lifesciences #innovation #biotechinvestment #danishbiotech #researchanddevelopment #biotechcompanies #bioinnovation Acesion Pharma | Adcendo | Ascendis Pharma | Bavarian Nordic | Genmab | Hoba Therapeutics | IO Biotech | Minervax ApS | Zealand Pharma

AltruBio Inc., a clinical-stage biotechnology company based in San Francisco, CA, has raised $225 million in a Series B funding round. The financing was led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital, and existing investors aMoon Fund and Blackstone Multi-Asset Investing, among others. This significant influx of capital will enable AltruBio to advance the clinical development of its lead product candidate, ALTB-268, an immune checkpoint enhancer (ICE) PSGL-1 agonist antibody. Specifically, the funds will support ongoing and planned Phase 2 clinical trials evaluating ALTB-268 as a potential treatment for ulcerative colitis (UC), a form of inflammatory bowel disease. AltruBio aims to leverage this financing to further its pipeline of immunotherapies. https://lnkd.in/gmhpkapq

Merger & Acquisition Life Science / Healthcare 2023 Landscape Review Already this year we’ve seen Sanofi enter an agreement to acquire all outstanding shares of Inhibrx, Inc., as well as Johnson & Johnson’s recent acquisition of Ambrx Biopharma. 🔍 A quick review of Beacon Deals & Companies showed we identified 86 M&A deals last year 🔍 So, here’s one from every month … 🤝December: Bristol Myers Squibb Announced Definitive Merger Agreement to Acquire RayzeBio 🤝November: Selecta Biosciences Announces Merger with Cartesian Therapeutics 🤝October: Kyowa Kirin, Inc.- U.S. to Acquire Orchard Therapeutics 🤝September: Renovaro Biosciences Inc. and GEDiCube Sign Definitive Agreement to Combine 🤝August: Serina Therapeutics, Inc. and AgeX Therapeutics, Inc. Enter into Merger Agreement 🤝July: Biogen to Acquire Reata Pharmaceuticals, Inc. 🤝June: Talaris Therapeutics and Tourmaline Bio Entered into Merger Agreement 🤝May: Pyxis Oncology to Acquire Apexigen 🤝April: NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV 🤝March: Flamingo Therapeutics Signed a Definitive Merger Agreement with Dynacure 🤝February: Kite Pharma Completed the Acquisition of Tmunity Therapeutics Incorporated 🤝January: Leap Therapeutics Acquires Flame Biosciences If you’re interested in learning more about how Beacon tracks the company and deal data in the Cell Therapy, Gene Therapy, RNA, ADC, Bispecific, Immune Tolerance, Checkpoint, Cytokine, DDR, TPD, Microbiome, Cancer Vaccine, or Oncolytic Virus landscapes drop me a message. #drugdevelopment #pharma #MnA #biotech